Fractyl Health Inc. (GUTS)
NASDAQ: GUTSHealth CareMedical/Dental InstrumentsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
GUTS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $10.88M
- EPS (TTM)
- -$3.14
- Dividend yield
- None
- 52-week range
- 0.784 – 29.34
- Day range
- 0.784 – 0.9698
- Volume / Avg
- 333.60K / 504.39K
- Beta
- —
- Shares outstanding
- 13.26M
52-week range
GUTS stock today
Shares of Fractyl Health (GUTS) finished lower on Nov 20 at $0.82, a drop of 14.16% or $0.1353 per share, versus the S&P 500's 3.70% decline. Shares are 97.2% below their 52-week high of $29.34, set on Dec 12, 2025 and 4.6% above the 52-week low of $0.784, near the bottom of the past year's range. GUTS is down 96.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 95.1%.
Fractyl Health has posted a net loss over the last twelve months (EPS of -$3.14), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Fractyl Health
Company profileFractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. The company also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- CEO
- Dr. Harith Rajagopalan M.D., Ph.D.
- Headquarters
- Burlington, MA
- Employees
- 100
- IPO year
- 2024
- Website
- fractyl.com
Financial highlights
Full financialsIn fiscal 2025, Fractyl Health generated $0 in revenue, down 100.0% from fiscal 2024, its first annual decline since 2024. Fractyl Health reported a net loss of $141.0 million, compared with a loss of $68.7 million a year earlier. Diluted earnings per share came in at -$1.86.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Revenue | $0 | $93.00K | $120.00K |
| Growth | -100.00% | -22.50% | — |
| Net income | $-140.95M | $-68.69M | $-77.09M |
| EPS (diluted) | $-1.86 | $-1.62 | $-45.29 |
Analyst forecast
ForecastConsensus (7 analysts)
strong_buy
Avg. price target
$60.40+7265.85%
- Strong buy 0
- Buy 6
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-4.20 vs $-1.59
- Surprise
- -164.15%
GUTS news
All GUTS news- Fractyl Health, Inc. Discloses Separation and Consulting Agreements with Former President Jay CaplanNasdaq
- Fractyl Health, Inc. Reports Third Quarter 2026 Financial Results and Business UpdatesNasdaq
- Fractyl Health (GUTS) Q3 2026 Earnings Call TranscriptNasdaq
- Fractyl Health to Report Third Quarter 2026 Financial Results and Provide Business Updates on November 12, 2026GlobeNewswire
- Fractyl Health Strengthens Revita Patent Portfolio as It Advances Toward FDA Submission and Potential CommercializationGlobeNewswire
- Fractyl Health Consensus Price Target Increased by 917.27% to $46.07Nasdaq
- Fractyl Health, Inc. Announces Strategic Reprioritization, 45% Workforce Reduction, and Leadership ChangesNasdaqGUTS, LEN.B
- Pre-Market Most Active for Oct 16, 2026 : TSLL, GUTS, NOK, VRNS, TQQQ, TSLA, SPCX, STLA, IONQ, BAC, LYG, JOBYNasdaqTSLL, GUTS, NOK, VRNS
Fractyl Health peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| FEMYFemasys Inc. | 1.24 | 0.00% | $10.73M | vs GUTS |
| PAVMPAVmed Inc. | 1.14 | -5.42% | $9.08M | vs GUTS |
| SNWVSANUWAVE Health Inc. | 1.50 | -5.66% | $12.90M | vs GUTS |
| AEMDAethlon Medical Inc. | 5.46 | +12.81% | $8.78M | vs GUTS |
| CTSOCytosorbents Corporation | 4.16 | -18.91% | $13.12M | vs GUTS |
| PLSMPulsenmore Ltd. | 1.29 | -4.44% | $8.39M | vs GUTS |
| SINTSiNtx Technologies Inc. | 1.10 | -8.74% | $8.31M | vs GUTS |
| SKYASkyAI Inc. | 2.18 | -45.50% | $7.82M | vs GUTS |
Indexes, lists and sector
Fractyl Health stock FAQ
What is Fractyl Health's stock price today?
GUTS last traded at $0.82 as of Nov 20, 4:00 PM EST, down 14.16% on the day. Prices are delayed at least 15 minutes.
Does Fractyl Health pay a dividend?
No. Fractyl Health does not currently pay a regular cash dividend.
Who is Fractyl Health's CEO?
Dr. Harith Rajagopalan M.D., Ph.D. is the chief executive officer of Fractyl Health Inc., which has about 100 employees.
Has GUTS ever split its stock?
Yes. The most recent GUTS stock split was a 1-for-12 split on Oct 5, 2026.
What is the GUTS 52-week high?
The 52-week high for GUTS is $29.34 and the 52-week low is $0.784. The stock is currently 97.2% below its high.